As previously announced by Bionik Laboratories Corp. (the “Company”), and in relation to its commencement of certain cost-cutting measures to maximize available resources, the Company considered decreasing the size of its Board of Directors (the “Board”), with voluntary resignations of one or more directors. As a result, four of the Company’s seven directors voluntarily resigned from the Board, as follows: On June 22, 2023, Charles Matine, an independent director of the Company, as well as a member of its Audit Committee, resigned from all such positions with the Company.

Mr. Matine’s resignation as a director was not due to a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On June 22, 2023, Andre-Jacques Auberton Herve, the Company’s Chairman of the Board, resigned as Chairman and as a member of the Board. Mr. Auberton Herve’s resignation as a director was not due to a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On June 22, 2023, Joseph Martin, an independent director of the Company, the Chairman of the Audit Committee of the Company as well as a member of its Compensation Committee, resigned from all such positions with the Company. Mr. Martin’s resignation as a director was not due to a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On June 22, 2023, Audrey Thevenon, an independent director of the Company, as well as a member of its Compensation Committee, resigned from all such positions with the Company.

Dr. Thevenon’s resignation as a director was not due to a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The remaining Board members of the Company are Rich Russo Jr., its CEO, Remi Gaston-Dreyfus and Michal Prywata.